1. Home
  2. DVAX

as 10-07-2025 3:29pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Founded: 1996 Country:
United States
United States
Employees: N/A City: EMERYVILLE
Market Cap: 1.2B IPO Year: 2004
Target Price: $26.50 AVG Volume (30 days): 1.7M
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.42 EPS Growth: N/A
52 Week Low/High: $9.20 - $14.63 Next Earning Date: 11-06-2025
Revenue: $316,268,000 Revenue Growth: 26.66%
Revenue Growth (this year): 23.23% Revenue Growth (next year): 16.57%

Stock Insider Trading Activity of Dynavax Technologies Corporation (DVAX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Myers Scott Dunseth DVAX N/A Aug 22 '25 Buy $10.82 3,800 $41,116.00 35,004
Deep Track Biotechnology Master Fund, Ltd. DVAX N/A Aug 22 '25 Sell $10.59 970,143 $10,273,814.37 15,726,349
Deep Track Biotechnology Master Fund, Ltd. DVAX N/A Aug 21 '25 Sell $11.03 1,094,994 $12,077,783.82 15,726,349

Share on Social Networks: